Current Report Filing (8-k)
March 18 2019 - 4:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date
of earliest event reported):
March 18, 2019
Mustang Bio, Inc.
(Exact Name of Registrant
as Specified in Charter)
Delaware
|
|
001-38191
|
|
47-3828760
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Gansevoort
Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act.
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
|
Item
2.02
|
Results
of Operations and Financial Condition.
|
On March 18, 2019,
Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year
ended December 31, 2018. A copy of such press release is being furnished as Exhibit 99.1 to this report
.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
The following exhibit is furnished herewith:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
MUSTANG BIO, INC.
|
|
(Registrant)
|
Date: March 18, 2019
|
|
|
By:
|
/s/ Manuel Litchman, M.D.
|
|
Name:
|
Manuel Litchman, M.D.
|
|
Title:
|
President and Chief Executive Officer
|
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024